Home › Funds › PFM Health Sciences, LP › AMLX

PFM Health Sciences, LP position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

PFM Health Sciences, LP reported holding 282,434 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$8.2M, representing 0.84% of its reported portfolio and ranking #45 among its reported holdings. PFM Health Sciences, LP has disclosed AMLX holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)282.43K sh
Reported value held$8.22M
Portfolio Weight0.84%
First reportedQ1 2025
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How PFM Health Sciences, LP's AMLX position evolved

PFM Health Sciences, LP first disclosed a stake in AMLX in Q1 2025 at 834,135 shares (US$3.0M). The position peaked in Q3 2026 at 282,434 shares, worth US$8.2M. Across 7 filings, PFM Health Sciences, LP increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 282,434 shares valued at US$8.2M — an increase of 138,734 shares quarter over quarter.. Notable position changes include a 40% trim in Q3 2025 (shares fell 11% over the following quarter), a 69% trim in Q4 2025 (shares rose 15% over the following quarter), a 97% increase in Q3 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 834.13K $2.95M New
Q2 2025 732.26K $4.69M Reduce
Q3 2025 436.16K $5.93M Reduce
Q4 2025 134.55K $1.63M Reduce
Q1 2026 145.28K $2.02M Add
Q2 2026 143.70K $2.58M Reduce
Q3 2026 282.43K $8.22M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in AMLX — the largest reported positions include TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M), PERCEPTIVE ADVISORS LLC (US$149.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has PFM Health Sciences, LP held AMLX?

PFM Health Sciences, LP has disclosed AMLX holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is PFM Health Sciences, LP's current position in AMLX?

As of Q3 2026, PFM Health Sciences, LP holds 282.43K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $8.22M, representing 0.84% of its reported portfolio and ranking #45.

Has PFM Health Sciences, LP been buying or selling AMLX?

In the latest 13F filing (Q3 2026), PFM Health Sciences, LP increased its position in AMLX. The position peaked in Q3 2026 at 282.43K shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.